Atnahs Pharma Denmark ApS: Financial statements 2026
CVR: 36699051
Source: annual report 2026, Danish Business Authority
01/04/2025 – 31/03/2026
Atnahs Pharma Denmark ApS (CVR 36699051) has filed annual accounts for 2026. In 2026, the company reported revenue of EUR 52,583,756 and a net result of EUR 12,487 compared with DKK 47,843 the year before. That is a decrease of 26.4% compared with the year before. The profit margin was 0%. Equity in the 2026 report amounted to EUR 2,094,136. The solvency ratio was 6.3%.
- Revenue
- EUR 52,583,756
- Gross Profit
- EUR -1,600,069
- Profit/Loss
- EUR 12,487
- Equity
- EUR 2,094,136
- Total Assets
- EUR 33,136,851
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2026 | 52.6 mio. EUR | -1.6 mio. EUR | 12 t. EUR | 2.1 mio. EUR | 0 |
| 2025 | 71.4 mio. | 1.4 mio. | 48 t. | 2.1 mio. | 0 |
| 2024 | 91.3 mio. EUR | 925 t. EUR | 20 t. EUR | 2 mio. EUR | - |
| 2023 | 517.2 mio. | -19.4 mio. | 14.7 mio. | 14.9 mio. | - |
| 2022 | - | 9.8 mio. | 3.6 mio. | 142 t. | - |
Official annual report
Find more companies like Atnahs Pharma Denmark ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2026
As of June 9, 2026, Neeshe Bhikhubhai Williams has left the board of directors of Atnahs Pharma Denmark ApS.
As of June 9, 2026, Christoph Michael Habereder is registered as director of Atnahs Pharma Denmark ApS.
As of June 9, 2026, Neeshe Bhikhubhai Williams has stepped down as director of Atnahs Pharma Denmark ApS.
As of March 24, 2026, Mohammad Muqtadir Samy has joined the board of directors of Atnahs Pharma Denmark ApS.
As of March 24, 2026, Amit Vijaykumar Patel has left the board of directors of Atnahs Pharma Denmark ApS.
As of March 23, 2026, Mohammad Muqtadir Samy has left the board of directors of Atnahs Pharma Denmark ApS.
As of February 17, 2026, Twan Johannes Anna Nouwen has joined the board of directors of Atnahs Pharma Denmark ApS.
As of February 17, 2026, Mohammad Muqtadir Samy has joined the board of directors of Atnahs Pharma Denmark ApS.
As of February 17, 2026, Christoph Michael Habereder has joined the board of directors of Atnahs Pharma Denmark ApS.
As of February 17, 2026, Santsagar Patel has left the board of directors of Atnahs Pharma Denmark ApS.
About Atnahs Pharma Denmark ApS
Atnahs Pharma Denmark ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Pharmamentum ApS. The management consists of Christoph Michael Habereder. The board consists of Mohammad Muqtadir Samy (chair), Christoph Michael Habereder and Twan Johannes Anna Nouwen. The company is owned by Atnahs Pharma UK Limited. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported revenue of EUR 52,583,756 and a net result of EUR 12,487 compared with DKK 47,843 the year before. Equity in the 2026 report amounted to EUR 2,094,136.